Literature DB >> 32208489

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

Anna L Brown1,2,3, Peer Arts1,2, Catherine L Carmichael4, Milena Babic1,2, Julia Dobbins1,2, Chan-Eng Chong1, Andreas W Schreiber5,6, Jinghua Feng2,6, Kerry Phillips7, Paul P S Wang6, Thuong Ha1,2, Claire C Homan1,2, Sarah L King-Smith1,2, Lesley Rawlings1, Cassandra Vakulin1, Andrew Dubowsky1, Jessica Burdett1, Sarah Moore1, Grace McKavanagh1, Denae Henry1, Amanda Wells1, Belinda Mercorella1, Mario Nicola1, Jeffrey Suttle1, Ella Wilkins8, Xiao-Chun Li2, Joelle Michaud8, Peter Brautigan1,2, Ping Cannon8, Meryl Altree7, Louise Jaensch7, Miriam Fine7, Carolyn Butcher2,9, Richard J D'Andrea2, Ian D Lewis4,10, Devendra K Hiwase3,9,11, Elli Papaemmanuil12, Marshall S Horwitz13, Georges Natsoulis14, Hugh Y Rienhoff14, Nigel Patton15, Sally Mapp16, Rachel Susman17, Susan Morgan18, Julian Cooney19, Mark Currie20, Uday Popat21, Tilmann Bochtler22, Shai Izraeli23,24, Kenneth Bradstock25, Lucy A Godley26, Alwin Krämer22, Stefan Fröhling27,28, Andrew H Wei29, Cecily Forsyth30, Helen Mar Fan17, Nicola K Poplawski7,31, Christopher N Hahn1,2,3, Hamish S Scott1,2,3,6.   

Abstract

First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic mutations detected in 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families detected 2 partial gene deletions, 3 novel mutations, and 5 recurrent mutations as the germline RUNX1 alterations leading to FPD-MM. Combining genomic data from the families reported herein with aggregated published data sets resulted in 130 germline RUNX1 families, which allowed us to investigate whether specific germline mutation characteristics (type, location) could explain the large phenotypic heterogeneity between patients with familial platelet disorder and different HMs. Comparing the somatic mutational signatures between the available familial (n = 35) and published sporadic (n = 137) RUNX1-mutated AML patients showed enrichment for somatic mutations affecting the second RUNX1 allele and GATA2. Conversely, we observed a decreased number of somatic mutations affecting NRAS, SRSF2, and DNMT3A and the collective genes associated with CHIP and epigenetic regulation. This is the largest aggregation and analysis of germline RUNX1 mutations performed to date, providing a unique opportunity to examine the factors underlying phenotypic differences and disease progression from FPD to MM.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32208489      PMCID: PMC7094007          DOI: 10.1182/bloodadvances.2019000901

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  84 in total

1.  Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.

Authors:  I Antony-Debré; N Duployez; M Bucci; S Geffroy; J-B Micol; A Renneville; N Boissel; N Dhédin; D Réa; B Nelken; C Berthon; T Leblanc; M-J Mozziconacci; R Favier; P G Heller; O Abdel-Wahab; H Raslova; V Latger-Cannard; C Preudhomme
Journal:  Leukemia       Date:  2015-08-28       Impact factor: 11.528

2.  Targeted next-generation sequencing of familial platelet disorder with predisposition to acute myeloid leukaemia.

Authors:  Karl Haslam; Stephen E Langabeer; Amjad Hayat; Eibhlin Conneally; Elisabeth Vandenberghe
Journal:  Br J Haematol       Date:  2015-11-03       Impact factor: 6.998

3.  Platelet CD34 expression and α/δ-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders.

Authors:  Anna E Marneth; Waander L van Heerde; Konnie M Hebeda; Britta A P Laros-van Gorkom; Wideke Barteling; Brigith Willemsen; Aniek O de Graaf; Annet Simons; Joop H Jansen; Frank Preijers; Marjolijn C Jongmans; Bert A van der Reijden
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

4.  Chemogenomic Landscape of RUNX1-mutated AML Reveals Importance of RUNX1 Allele Dosage in Genetics and Glucocorticoid Sensitivity.

Authors:  Laura Simon; Vincent-Philippe Lavallée; Marie-Eve Bordeleau; Jana Krosl; Irène Baccelli; Geneviève Boucher; Bernhard Lehnertz; Jalila Chagraoui; Tara MacRae; Réjean Ruel; Yves Chantigny; Sébastien Lemieux; Anne Marinier; Josée Hébert; Guy Sauvageau
Journal:  Clin Cancer Res       Date:  2017-08-30       Impact factor: 12.531

5.  Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions.

Authors:  Mylène Béri-Dexheimer; Véronique Latger-Cannard; Christophe Philippe; Céline Bonnet; Pascal Chambon; Virginie Roth; Marie-José Grégoire; Pierre Bordigoni; Thomas Lecompte; Bruno Leheup; Philippe Jonveaux
Journal:  Eur J Hum Genet       Date:  2008-05-14       Impact factor: 4.246

Review 6.  Familial myelodysplasia and acute myeloid leukaemia--a review.

Authors:  Carolyn Owen; Michael Barnett; Jude Fitzgibbon
Journal:  Br J Haematol       Date:  2008-01       Impact factor: 6.998

7.  C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies.

Authors:  Kateřina Staňo Kozubík; Lenka Radová; Michaela Pešová; Kamila Réblová; Jakub Trizuljak; Karla Plevová; Veronika Fiamoli; Jaromír Gumulec; Helena Urbánková; Tomáš Szotkowski; Jiří Mayer; Šárka Pospíšilová; Michael Doubek
Journal:  Int J Hematol       Date:  2018-08-06       Impact factor: 2.490

8.  The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Authors:  Hamish S Scott; Christopher N Hahn; Devendra K Hiwase; Deepak Singhal; Li Yan A Wee; Monika M Kutyna; Rakchha Chhetri; Joel Geoghegan; Andreas W Schreiber; Jinghua Feng; Paul P-S Wang; Milena Babic; Wendy T Parker; Smita Hiwase; Suzanne Edwards; Sarah Moore; Susan Branford; Teodora Kuzmanovic; Nimit Singhal; Raghu Gowda; Anna L Brown; Peer Arts; Luen B To; Peter G Bardy; Ian D Lewis; Richard J D'Andrea; Jaroslaw P Maciejewski
Journal:  Leukemia       Date:  2019-05-14       Impact factor: 11.528

9.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

Authors:  F Favero; T Joshi; A M Marquard; N J Birkbak; M Krzystanek; Q Li; Z Szallasi; A C Eklund
Journal:  Ann Oncol       Date:  2014-10-15       Impact factor: 32.976

Review 10.  Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Authors:  Peter Valent; Wolfgang Kern; Gregor Hoermann; Jelena D Milosevic Feenstra; Karl Sotlar; Michael Pfeilstöcker; Ulrich Germing; Wolfgang R Sperr; Andreas Reiter; Dominik Wolf; Michel Arock; Torsten Haferlach; Hans-Peter Horny
Journal:  Int J Mol Sci       Date:  2019-02-12       Impact factor: 5.923

View more
  20 in total

Review 1.  The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition.

Authors:  Rashmi Kanagal-Shamanna
Journal:  Curr Hematol Malig Rep       Date:  2021-05-24       Impact factor: 3.952

Review 2.  Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).

Authors:  Anna L Brown; Christopher N Hahn; Hamish S Scott
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 3.  Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors:  Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 11.528

4.  Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.

Authors:  Michelle C Krutein; Matthew R Hart; Donovan J Anderson; Jasmin Jeffery; Andriana G Kotini; Jin Dai; Sylvia Chien; Michaela DelPriore; Sara Borst; Jean Ann Maguire; Deborah L French; Paul Gadue; Eirini P Papapetrou; Siobán B Keel; Pamela S Becker; Marshall S Horwitz
Journal:  Blood Adv       Date:  2021-02-09

Review 5.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

Review 6.  Germline risk of clonal haematopoiesis.

Authors:  Alexander J Silver; Alexander G Bick; Michael R Savona
Journal:  Nat Rev Genet       Date:  2021-05-13       Impact factor: 53.242

7.  Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia.

Authors:  Yizhen Li; Wentao Yang; Meenakshi Devidas; Stuart S Winter; Chimene Kesserwan; Wenjian Yang; Kimberly P Dunsmore; Colton Smith; Maoxiang Qian; Xujie Zhao; Ranran Zhang; Julie M Gastier-Foster; Elizabeth A Raetz; William L Carroll; Chunliang Li; Paul P Liu; Karen R Rabin; Takaomi Sanda; Charles G Mullighan; Kim E Nichols; William E Evans; Ching-Hon Pui; Stephen P Hunger; David T Teachey; Mary V Relling; Mignon L Loh; Jun J Yang
Journal:  J Clin Invest       Date:  2021-06-24       Impact factor: 14.808

8.  Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies.

Authors:  Amy M Trottier; Lawrence J Druhan; Ira L Kraft; Amanda Lance; Simone Feurstein; Maria Helgeson; Jeremy P Segal; Soma Das; Belinda R Avalos; Lucy A Godley
Journal:  Blood Adv       Date:  2020-10-27

Review 9.  Cohesin mutations in myeloid malignancies.

Authors:  Johann-Christoph Jann; Zuzana Tothova
Journal:  Blood       Date:  2021-08-26       Impact factor: 25.476

10.  Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Authors:  Jean Pegliasco; Pierre Hirsch; Christophe Marzac; Françoise Isnard; Jean-Côme Meniane; Caroline Deswarte; Philippe Pellet; Céline Lemaitre; Gwendoline Leroy; Graciela Rabadan Moraes; Hélène Guermouche; Barbara Schmaltz-Panneau; Florence Pasquier; Chrystelle Colas; Patrick R Benusiglio; Odile Bera; Jean-Henri Bourhis; Eolia Brissot; Olivier Caron; Samy Chraibi; Pascale Cony-Makhoul; Christine Delaunay-Darivon; Simona Lapusan; Flore Sicre de Fontbrune; Pascal Fuseau; Albert Najman; William Vainchenker; François Delhommeau; Jean-Baptiste Micol; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.